On (i) The sale of a majority stake in Max Healthcare Institute Limited to KKR, including through a composite scheme of arrangement sanctioned by the Mumbai NCLT, and subsequent exit of the Max Group from the healthcare business in a USD 1.7 billion deal (ii) The share swap transaction of 21.87% stake held by Mitsui Sumitomo Insurance Company Limited in Max Life Insurance Company Limited, with 20.57% stake in Max Financial Services Limited, a listed company (iii) The joint venture with Axis Bank Limited (iv) The sale of Max India’s 51% stake in Max Bupa to True North, for USD 72 million
